Novavax & Serum Institute announced that Drugs Controller General of India has granted emergency use authorization for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant; vaccine will be manufactured by SII under brand name Covovax: Novavax— ANI (@ANI) December 28, 2021
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


